p53 mediates DNA damaging drug-induced apoptosis through a caspase-9-dependent pathway in SH-SY5Y neuroblastoma cells

Molecular Cancer Therapeutics

Volumn 1, Issue 9, 2002, Pages 679-686

  Cui, Hongjuan ^a   Schroering, Allen ^a   Ding, Han Fei ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASP9 PROTEIN, HUMAN; CASPASE; CASPASE 9; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; CYTOCHROME C; DNA FRAGMENT; DOXORUBICIN; ETOPOSIDE; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL NUCLEUS; DNA DAMAGE; DOSE RESPONSE; ENZYME ACTIVATION; ENZYMOLOGY; FLUORESCENCE MICROSCOPY; GENETIC TRANSCRIPTION; HUMAN; IMMUNOBLOTTING; METABOLISM; MITOCHONDRION; NEUROBLASTOMA; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CASPASE 9; CASPASES; CELL NUCLEUS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; CYTOCHROME C GROUP; DNA DAMAGE; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ENZYME ACTIVATION; ETOPOSIDE; GENES, P53; HUMANS; IMMUNOBLOTTING; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; NEUROBLASTOMA; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036636475     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Schmitt, C., and Lowe, S. Apoptosis and therapy. J. Pathol., 187: 127-137, 1999. (Pubitemid 29009842)
2. Nagata, S. Apoptosis by death factor. Cell, 88: 355-365, 1997. (Pubitemid 27131377)
3. Green, D. R., and Reed, J. C. Mitochondria and apoptosis. Science (Wash. DC), 281: 1309-1312, 1998. (Pubitemid 28406816)
4. Hengartner, M. The biochemistry of apoptosis. Nature (Lond.), 407: 770-776, 2000.
5. Yang, X., Chang, H. Y., and Baltimore, D. Autoproteolytic activation of pro-caspases by oligomerization. Mol. Cell, 1: 319-325, 1998. (Pubitemid 128378672)
6. Muzio, M., Stockwell, B. R., Stennicke, H. R., Salvesen, G. S., and Dixit, V. M. An induced proximity model for caspase-8 activation. J. Biol. Chem., 273: 2926-2930, 1998. (Pubitemid 28133943)
7. Liu, X. S., Kim, C. N., Yang, J., Jemmerson, R., and Wang, X. D. Induction of apoptotic program in cell-free extracts - requirement for dATP and cytochrome c. Cell, 86: 147-157, 1996. (Pubitemid 26256586)
8. Zou, H., Henzel, W. J., Liu, X., Lutschg, A., and Wang, X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell, 90: 405-413, 1997. (Pubitemid 27347231)
9. Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell, 91: 479-489, 1997. (Pubitemid 27508237)
10. Wang, X. The expanding role of mitochondria in apoptosis. Gene Dev., 15: 2922-2933, 2001. (Pubitemid 33078942)
11. Li, H., Zhu, H., Xu, C-J., and Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell, 94: 491-501, 1998. (Pubitemid 28391865)
12. Luo, X., Budihardjo, I., Zou, H., Slaughter, C., and Wang, X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell, 94: 481-490, 1998. (Pubitemid 28391864)
13. Wei, M. C., Zong, W-X., Cheng, E. H-Y., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. Proapoptotic Bax and Bak: a requisite gateway to mitochondrial dysfunction and death. Science (Wash. DC), 292: 727-730, 2001. (Pubitemid 32385543)
14. Vogelstein, B., Lane, D., and Levine, A. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000.
15. Rich, T., Allen, R., and Wyllie, A. Defying death after DNA damage. Nature (Lond.), 407: 777-783, 2000.
16. Kuida, K., Haydar, T. F., Kuan, C-Y., Gu, Y., Taya, C., Karasuyama, H., Su, M. S-S., Rakic, P., and Flavell, R. A. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell, 94: 325-337, 1998. (Pubitemid 28376077)
17. Hakem, R., Hakem, A., Duncan, G. S., Henderson, J. T., Woo, M., Soengas, M. S., Elia, A., de la Pompa, J. L., Kagi, D., Khoo, W., Potter, J., Yoshida, R., Kaufman, S. A., Lowe, S. W., Penninger, J. M., and Mak, T. W. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell, 94: 339-352, 1998. (Pubitemid 28376078)
18. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53- dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993. (Pubitemid 23132162)
19. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993. (Pubitemid 23132161)
20. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53- dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993. (Pubitemid 23289454)
21. Soengas, S. M., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., Cordon-Cardo, C., and Lowe, S. W. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature (Lond.), 409: 207-211, 2001. (Pubitemid 32144287)
22. Muller, M., Strand, S., Hug, H., Heinemann, E. M., Walczak, H., Hofmann, W. J., Stremmel, W., Krammer, P. H., and Galle, P. R. Druginduced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/ Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Investig., 99: 403-413, 1997. (Pubitemid 27414797)
23. Wu, G., Burns, T., McDonald, E., III, Jiang, W., Meng, R., Krantz, I., Kao, G., Gan, D-D., Zhou, J-Y., Muschel, R., Hamilton, S., Spinner, N., Markowitz, S., Wu, G., and El-Deiry, W. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 17: 141-143, 1997.
24. Lin, Y., Ma, W., and Benchimol, S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat. Genet., 26: 124-127, 2000.
25. Ding, H-F., Lin, Y-L., McGill, G., Juo, P., Zhu, H., Blenis, J., Yuan, J., and Fisher, D. Essential role for caspase-8 in transcription-independent apoptosis triggered by p53. J. Biol. Chem., 275: 38905-38911, 2000. (Pubitemid 32009229)
26. Brodeur, G., and Gastleberry, R. Neuroblastoma. In: P. Pizzo and D. Poplack (eds.), Principles and Practice of Pediatric Oncolgy, Ed. 3, pp. 761-797. Philadelphia: Lippincott-Raven Publishers, 1997.
27. Bown, N. Neuroblastoma tumor genetics: clinical and biological aspects. J. Clin. Pathol., 54: 897-910, 2001. (Pubitemid 34032883)
28. Fulda, S., Sieverts, H., Friesen, C., Herr, I., and Debatin, K. M. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res., 57: 3823-3829, 1997. (Pubitemid 27381230)
29. Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., and Reynolds, C. P. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res., 61: 6185-6193, 2001. (Pubitemid 32768583)
30. Tweddle, D., Malcolm, A., Bown, N., Pearson, A., and Lunec, J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res., 61: 8-13, 2001. (Pubitemid 32095689)
31. O'Connor, L., Harris, A. W., and Strasser, A. CD95 (Fas/APO-1) and p53 signal apoptosis independently in diverse cell types. Cancer Res., 60: 1217-1220, 2000. (Pubitemid 30151986)
32. Owen-Schaub, L. B., Zhang, W., Cusack, J. C., Angelo, L. S., Santee, S. M., Fujiwara, T., Roth, J. A., Deisseroth, A. B., Zhang, W. W., Kruzel, E., et al. Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. Mol. Cell. Biol., 15: 3032-3040, 1995.
33. Eggert, A., Grotzer, M. A., Zuzak, T. J., Wiewrodt, B. R., Ho, R., Ikegaki, N., and Brodeur, G. M. Resistance to tumor necrosis factorrelated apoptosis-inducing ligand-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res., 61: 1314-1319, 2001. (Pubitemid 34292549)
34. Varfolomeev, E. E., Schuchmann, M., Luria, V., Chiannilkulchai, N., Bechmann, J. S., Mett, I. L., Rebrikov, D., Brodianski, V. M., Kemper, O. C., Kollet, O., Lapidot, T., Soffer, D., Sobe, T., Avraham, K. B., Goncharov, T., Joltmann, H., Lonai, P., and Wallach, D. Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity, 9: 267- 276, 1998.
35. Juo, P., Kuo, C. J., Yuan, J., and Blenis, J. Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr. Biol., 8: 1001-1008, 1998. (Pubitemid 28448072)
36. Ory, D., Neugeboren, B., and Mulligan, R. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc. Natl. Acad. Sci. USA, 93: 11400-11406, 1996. (Pubitemid 26347133)
37. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., and Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63: 1129-1136, 1990. (Pubitemid 120035062)
38. Foster, S., Demers, G., Etscheid, B., and Galloway, D. The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. J. Virol., 68: 5698-5705, 1994.
39. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88: 593-602, 1997. (Pubitemid 27152402)
40. Srinivasula, S. M., Ahmad, M., Fernandes-Alnemri, T., and Alnemri, E. S. Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol. Cell, 1: 949-957, 1998. (Pubitemid 128379256)
41. Herrmann, M., Lorenz, H-M., Voll, R., Grunke, M., Woith, W., and Kalden, J. R. A rapid and simple method for the isolation of apoptotic DNA fragments. Nucleic Acids Res., 22: 5506-5507, 1994.
42. Wozniak, A., and Ross, W. DNA damage as a basis for 4′-demethyl- epipodophyllotoxin- 9-(4,6-O-ethylidene-β-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Res., 43: 120-124, 1983. (Pubitemid 13172805)
43. Yang, L., Rowe, T., and Liu, L. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res., 45: 5872-5876, 1985. (Pubitemid 16218602)
44. Tewey, K., Rowe, T., Yang, L., Halligan, B., and Liu, L. Adriamyc-ininduced DNA damage mediated by mammalian DNA topoisomerase II. Science (Wash. DC), 226: 466-468, 1984. (Pubitemid 14012819)
45. Brown, J. P., and Pagano, M. Mechanism of p53 degradation. Biochim. Biophys. Acta, 1332: O1-O6, 1997. (Pubitemid 27211622)
46. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993. (Pubitemid 23346378)
47. Barak, Y., Juven, T., Haffner, R., and Oren, M. mdm2 expression is induced by wild-type p53 activity. EMBO J., 12: 461-468, 1993. (Pubitemid 23073692)
48. Goldstein, J., Waterhouse, N., Juin, P., Evan, G., and Green, D. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant. Nature Cell Biol., 2: 156-162, 2000.
49. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Wash. DC), 253: 49-53, 1991. (Pubitemid 21917115)
50. Komuro, H., Hayashi, Y., Kawamura, M., Hayashi, K., Kaneko, Y., Kamoshita, S., Hanada, R., Yamamoto, K., Hongo, T., Yamada, M., et al. Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res., 53: 5284-5288, 1993. (Pubitemid 23333400)
51. Vogan, K., Bernstein, M., Leclerc, J. M., Brisson, L., Brossard, J., Brodeur, G. M., Pelletier, J., and Gros, P. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res., 53: 5269-5273, 1993. (Pubitemid 23333398)
52. Imamura, J., Bartram, C., Berthold, F., Harms, D., Nakamura, H., and Koeffler, H. Mutation of the p53 gene in neuroblastoma and its relationship with N-myc amplification. Cancer Res., 53: 4053-4058, 1993. (Pubitemid 23267710)
53. Hosoi, G., Hara, J., Okamura, T., Osugi, Y., Ishihara, S., Fukuzawa, M., Okada, A., Okada, S., and Tawa, A. Low frequency of the p53 gene mutations in neuroblastoma. Cancer (Phila.), 73: 3087-3093, 1994. (Pubitemid 24170786)
54. Castresana, J. S., Bello, M. J., Rey, J. A., Nebreda, P., Queizan, A., Garcia-Miguel, P., and Pestana, A. No TP53 mutations in neuroblastomas detected by PCR-SSCP analysis. Genes Chromosomes Cancer, 10: 136-138, 1994. (Pubitemid 24155984)
55. Kusafuka, T., Fukuzawa, M., Oue, T., Komoto, Y., Yoneda, A., and Okada, A. Mutation analysis of p53 gene in childhood malignant solid tumors. J. Pediatr. Surg., 32: 1175-1180, 1997. (Pubitemid 27475893)
56. Moll, U. M., LaQuaglia, M., Benard, J., and Riou, G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl. Acad. Sci. USA, 92: 4407-4411, 1995.
57. Goldman, S. C., Chen, C. Y., Lansing, T. J., Gilmer, T. M., and Kastan, M. B. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am. J. Pathol., 148: 1381-1385, 1996. (Pubitemid 26135882)
58. Jasty, R., Lu, J., Irwin, T., Suchard, S., Clarke, M. F., and Castle, V. P. Role of p53 in the regulation of irradiation-induced apoptosis in neuroblastoma cells. Mol. Genet. Metab., 65: 155-164, 1998. (Pubitemid 28507136)
59. McKenzie, P. P., Guichard, S. M., Middlemas, D. S., Ashmun, R. A., Danks, M. K., and Harris, L. C. Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated. Clin. Cancer Res., 5: 4199-4207, 1999. (Pubitemid 30013806)
60. Teitz, T., Wei, T., Liu, D., Valentine, V., Valentine, M., Grenet, J., Lahti, J. M., and Kidd, V. J. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. Oncogene, 21: 1848-1858, 2002. (Pubitemid 34259187)
61. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299, 1995.
62. Rosse, T., Olivier, R., Monney, L., Rager, M., Conus, S., Fellay, I., Jansen, B., and Borner, C. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature (Lond.), 391: 496-499, 1998. (Pubitemid 28086551)
63. Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., and Tanaka, N. Noxa, a BH3-only member of the bcl-2 family and candidate mediator of p53-induced apoptosis. Science (Wash. DC), 288: 1053-1058, 2000. (Pubitemid 30324238)
64. Nakano, K., and Vousden, K. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell, 7: 683-694, 2001. (Pubitemid 32706359)
65. Yu, J., Zhang, L., Hwang, P., Kinzler, K., and Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell, 7: 673-682, 2001. (Pubitemid 32706358)
66. McCurrach, M. E., Connor, T. M., Knudson, C. M., Korsmeyer, S. J., and Lowe, S. W. bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA, 94: 2345-2349, 1997. (Pubitemid 27136877)
67. Soengas, M. S., Alarcon, R. M., Yoshida, H., Giaccia, A. J., Hakem, R., Mak, T. W., and Lowe, S. W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (Wash. DC), 284: 156-159, 1999. (Pubitemid 29282071)
68. Deloukas, P., Schuler, G. D., Gyapay, G., Beasley, E. M., Soderlund, C., Rodriguez-Tome, P., Hui, L., Matise, T. C., McKusick, K. B., Beckmann, J. S., Bentolila, S., Bihoreau, M., Birren, B. B., Browne, J., Butler, A., Castle, A. B., Chiannilkulchai, N., Clee, C., Day, P. J., Dehejia, A., Dibling, T., Drouot, N., Duprat, S., Fizames, C., Bentley, D. R., et al. A physical map of 30,000 human genes. Science (Wash. DC), 282: 744-746, 1998. (Pubitemid 28489386)
69. Bown, N., Cotterill, S., Lastowska, M., O'Neill, S., Pearson, A. D., Plantaz, D., Meddeb, M., Danglot, G., Brinkschmidt, C., Christiansen, H., Laureys, G., and Speleman, F. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med., 340: 1954-1961, 1999. (Pubitemid 29288271)
70. Plantaz, D., Mohapatra, G., Matthay, K. K., Pellarin, M., Seeger, R. C., and Feuerstein, B. G. Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am. J. Pathol., 150: 81-89, 1997. (Pubitemid 27027099)
71. Ambrosini, G., Adida, C., and Altieri, D. C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med., 3: 917-921, 1997. (Pubitemid 27353455)
72. Reed, J. C. The Survivin saga goes in vivo. J. Clin. Investig., 108: 965-969, 2001. (Pubitemid 32946070)
73. Islam, A., Kageyama, H., Takada, N., Kawamato, T., Takayasu, H., Isogai, E., Ohira, M., Hashizume, K., Kobayashi, H., Kaneko, Y., and Nakagawara, A. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene, 19: 617-623, 2000. (Pubitemid 30102912)
74. Azuhata, T., Scott, D., Takamizawa, S., Wen, J., Davidoff, A., Fukuzawa, M., and Sandler, A. The inhibitor of apoptosis protein Survivin is associated with high-risk behavior of neuroblastoma. J. Pediatr. Surg., 36: 1785-1791, 2001. (Pubitemid 33131683)
75. Tajiri, T., Tanaka, S., Shono, K., Kinoshita, Y., Fujii, Y., Suita, S., Ihara, K., and Hara, T. Quick quantitative analysis for gene dosages associated with prognosis in neuroblastoma. Cancer Lett., 166: 89-94, 2001. (Pubitemid 32274289) Health